ReviewEuropean journal of radiology2015
Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment.
Review in European journal of radiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 116 citations in OpenAlex.
- Biomarker study of pembrolizumab in patients with advanced rare cancers.Cell reports. Medicine · 2026Trial
- Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial.Journal for immunotherapy of cancer · 2022Trial
- Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors.The oncologist · 2021Trial
- Phase 2 study of pembrolizumab in patients with advanced rare cancers.Journal for immunotherapy of cancer · 2020Trial
- Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma.Journal for immunotherapy of cancer · 2019Trial
- PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Trial
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.Lancet (London, England) · 2016Trial
- Phase 2 Study of Monotherapy with Pembrolizumab for Advanced Adrenocortical Carcinoma.Journal of immunotherapy and precision oncology · 2025Article
- [Advances in Pseudoprogression of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Review
- Tumor therapeutics in the era of "RECIST": past, current insights, and future prospects.Oncology reviews · 2024Review
- Advanced non-small-cell lung cancer treated with first-line pembrolizumab plus chemotherapy: tumor response dynamics as a marker for survival.European radiology · 2023Article
- A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma.Cancers · 2023Article
- A novel four-gene signature predicts immunotherapy response of patients with different cancers.Journal of clinical laboratory analysis · 2022Article
- Article
- Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial.Cancer chemotherapy and pharmacology · 2022Article
- Pulmonary adverse events associated with hypertension in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors.Frontiers in pharmacology · 2022Article
- Negative correlations of psychological distress with quality of life and immunotherapy efficacy in patients with advanced NSCLC.American journal of cancer research · 2022Article
- Evaluation of Response to Immune Checkpoint Inhibitors Using a Radiomics, Lesion-Level Approach.Cancers · 2021Article
- Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival.BMC cancer · 2021Article
- Imaging evaluation of lung cancer treated with PD-1/PD-L1 inhibitors.The British journal of radiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The recent advances in the clinical application of anti-cancer immunotherapeutic agents have opened a new arena for the treatment of advanced cancers. Cancer immunotherapy is associated with a variety of important radiographic features in the assessments of tumor response and immune-related adverse events, which calls for radiologists' awareness and in-depth knowledge on the topic. This article will provide the state-of-the art review and perspectives of cancer immunotherapy, including its molecular mechanisms, the strategies for immune-related response assessment on imaging and their pitfalls, and the emerging knowledge of radiologic manifestations of immune-related adverse events. The cutting edge clinical and radiologic investigations are presented to provide future directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.